These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [The role of allopurinol in prevention of recurrences in calcic calculosis]. Fiorelli C; Carini M; Nicita G; Rizzo M Minerva Urol; 1980; 32(3):153-60. PubMed ID: 7432330 [No Abstract] [Full Text] [Related]
23. [Calcium lithiasis: uric acid under question]. Petit C Nephrologie; 1984; 5(5):192-4. PubMed ID: 6531055 [TBL] [Abstract][Full Text] [Related]
24. Calcium oxalate renal stones. Prien EL Annu Rev Med; 1975; 26():173-9. PubMed ID: 1096755 [No Abstract] [Full Text] [Related]
25. Formation of a single calcium stone of renal origin. Clinical and laboratory characteristics of patients. Strauss AL; Coe FL; Parks JH Arch Intern Med; 1982 Mar; 142(3):504-7. PubMed ID: 7065787 [TBL] [Abstract][Full Text] [Related]
27. Biochemical and dietary factors of uric acid stone formation. Trinchieri A; Montanari E Urolithiasis; 2018 Apr; 46(2):167-172. PubMed ID: 28246885 [TBL] [Abstract][Full Text] [Related]
28. Analysis of treatment results in uric acid lithiasis with and without hyperuricemia. Alken CE; May P; Braun JS Adv Exp Med Biol; 1974; 41():535-40. PubMed ID: 4832578 [No Abstract] [Full Text] [Related]
29. Endocrine and metabolic aspects of urology. Aetiology of stone formation in 145 renal stone patients. Transbol I; Frydendal N Acta Chir Scand Suppl; 1973; 433():137-53. PubMed ID: 4513504 [No Abstract] [Full Text] [Related]
30. Medical treatment of idiopathic calcium nephrolithiasis. Surian M; Malberti F; Colussi G; De Ferrari ME; Rombolà G; Benazzi E; Minetti L Contrib Nephrol; 1987; 58():172-5. PubMed ID: 3691120 [No Abstract] [Full Text] [Related]
31. Use of the discriminant index in dynamic treatment to reduce recurrence of calcium oxalate kidney stones. Perlberg S; Azoury R; Garti N; Sarig S Br J Urol; 1985 Oct; 57(5):500-4. PubMed ID: 2998532 [TBL] [Abstract][Full Text] [Related]
32. [Allopurinol in the treatment of gout and uric acid nephrolithiasis]. Zöllner N; Schattenkirchner M Dtsch Med Wochenschr; 1967 Apr; 92(14):654-60. PubMed ID: 6024539 [No Abstract] [Full Text] [Related]
33. Management of the stone former. Burns JR; Finlayson B Semin Urol; 1984 Feb; 2(1):34-44. PubMed ID: 6463460 [No Abstract] [Full Text] [Related]
34. [The inhibition of uric acid synthesis with Allopurinol]. Holländer E Orv Hetil; 1968 Oct; 109(41):2272-4. PubMed ID: 5715143 [No Abstract] [Full Text] [Related]
35. The long-term effect of bendroflumethiazide on renal calcium and magnesium excretion and stone formation in patients with recurring renal stones. Jorgensen FS; Brünner S Scand J Urol Nephrol; 1974; 8(2):128-31. PubMed ID: 4838924 [No Abstract] [Full Text] [Related]
36. Impact of allopurinol treatment on the prevention of hyperuricosuric calcium oxalate lithiasis. Hofbauer J; Zechner O Eur Urol; 1988; 15(3-4):227-9. PubMed ID: 3215256 [TBL] [Abstract][Full Text] [Related]
37. [An unusual form of juvenile hyperuricemia with mechanical anuria]. Karcher GP; Tammen H Z Urol Nephrol; 1972 Nov; 65(11):827-32. PubMed ID: 4665914 [No Abstract] [Full Text] [Related]
38. [Allopurinol treatment of malignant uric acid lithiasis in a gouty patient with massive hyperuricosuria]. de Vries A; Frank M; Sperling O J Urol Nephrol (Paris); 1968; 74(4):403-8. PubMed ID: 5675122 [No Abstract] [Full Text] [Related]
39. Effects of allopurinol on gouty and non-gouty uric acid nephropathy. Ogryzlo MA; Urowitz MB; Weber HM; Houpt JB Ann Rheum Dis; 1966 Nov; 25(6 Suppl):673-80. PubMed ID: 5958697 [No Abstract] [Full Text] [Related]